Guide for Authors
Vaccine
is the most comprehensive and pre-eminent journal for those interested in vaccines
and vaccination, serving as an interface between academics, those in research and development, regulatory and governmental agencies,
charities, and health and industry professionals.
Types of paper
Vaccine
publishes primary research papers, review articles, short communications and letters on the following topics:
- Human Vaccines -
infectious diseases
- Human Vaccines - non-infectious diseases
- Veterinary Vaccines
- Immunology and Animal Models
- Vectors,
Adjuvants and Drug Delivery
- Production, manufacturing and Safety
- Regulatory, Societal and Legislation Aspects
For
more specifics please go to ARTICLE
TYPE - GUIDELINES
Contact details for submission
Papers should
be submitted using the
Vaccine online submission system,
http://ees.elsevier.com/jvac
Page charges
This journal has no page charges.
Ethics in publishing
For information on Ethics in publishing and Ethical
guidelines for journal publication see
http://www.elsevier.com/publishingethics and
http://www.elsevier.com/ethicalguidelines.
Policy and ethics
The work described in your article must have been carried out in accordance with
The
Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans http://www.wma.net/en/30publications/10policies/b3/index.html;
EU Directive 2010/63/EU for animal experiments http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm;
Uniform Requirements for manuscripts submitted to Biomedical journals http://www.icmje.org. This must be stated
at an appropriate point in the article.
Policy and ethics (additional information)
Informed consent
Investigations on human subjects must include a statement indicating that informed consent was obtained
after the nature and possible consequences of the studies had been fully explained.
Animal welfare
Authors using experimental
animals must state that their care was in accordance with institutional guidelines. For animals subjected to invasive procedures, the
anesthetic, analgesic and tranquilizing agents used, as well as the amounts and frequency of administration, must be stated.
Availability
of Materials
Publication of an article in
Vaccine is taken to imply that the authors are prepared to freely distribute
materials used in the published experiments (e.g. antibodies, cell lines) to academic researchers for their own use.
Conflict of interest
All authors must disclose any financial and personal relationships with other people
or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment,
consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. See
also
http://www.elsevier.com/conflictsofinterest.
Submission declaration
and verification
Submission of an article implies that the work described has not been published previously (except in the
form of an abstract or as part of a published lecture or academic thesis), that it is not under consideration for publication elsewhere,
that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out,
and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically
without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection
software iThenticate. See also
http://www.elsevier.com/editors/plagdetect.
Contributors
Each author is required to declare his or her individual contribution to the article: all authors must have
materially participated in the research and/or article preparation, so roles for all authors should be described. The statement that
all authors have approved the final article should be true and included in the disclosure.
Authorship
All authors should have made substantial contributions to all of the following: (1) the conception and design
of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for
important intellectual content, (3) final approval of the version to be submitted.
Changes
to authorship
This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted
manuscripts:
Before the accepted manuscript is published in an online issue: Requests to add or remove an author, or to rearrange
the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a)
the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from
all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes
confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the
Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform
the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship
has been agreed.
After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange
author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.
Reporting clinical trials
All randomised controlled trials submitted for publication should include a completed
Consolidated Standards of Reporting Trials (CONSORT) flow chart. Please refer to the CONSORT statement website at
http://www.consort-statement.org
for more information. This journal has adopted the proposal from the International Committee of Medical Journal Editors (ICMJE) which
require, as a condition of consideration for publication of clinical trials, registration in a public trials registry. Trials must register
at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of
the article. For this purpose, a clinical trial is defined as any research study that prospectively assigns human participants or groups
of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include
any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioural
treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained
in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the
assignment of the medical intervention is not at the discretion of the investigator) will not require registration. Further information
can be found at
http://www.icmje.org.
All scientific
communications describing immunogenicity, effectiveness, or efficacy of a human or veterinary vaccine must include the following details:
Vaccine characteristics: Vaccine lot number, manufacturer, dosing interval and number of doses, vaccine route of administration, if an
injection - the anatomic site of injection, technique for vaccine administration (if by injection, specify needle length), concomitant
vaccines administered, cold chain or storage effects if relevant, and a specification of what vaccine antigens and adjuvants were administered.
Subject characteristics: Age, race, ethnicity, body mass index or body weight, smoking status, gender, medical/immunologic status, and
concomitant drug use.
Copyright
Upon acceptance of an article, authors
will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright see
http://www.elsevier.com/copyright).
Acceptance of the agreement will ensure the widest possible dissemination of information. An e-mail will be sent to the corresponding
author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this
agreement.
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation
within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other
derivative works, including compilations and translations (please consult
http://www.elsevier.com/permissions). If excerpts
from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s)
in the article. Elsevier has preprinted forms for use by authors in these cases: please consult
http://www.elsevier.com/permissions.
Retained author rights
As an author you (or your employer or institution) retain certain rights; for details
you are referred to:
http://www.elsevier.com/authorsrights.
Role of the
funding source
You are requested to identify who provided financial support for the conduct of the research and/or preparation
of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation
of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such
involvement then this should be stated. Please see
http://www.elsevier.com/funding.
Funding body agreements and policies
Elsevier has established agreements and developed policies to allow authors whose
articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions
of their grant awards. To learn more about existing agreements and policies please visit
http://www.elsevier.com/fundingbodies.
Open access
This journal offers you the option of making your article freely available to all via the ScienceDirect
platform. To prevent any conflict of interest, you can only make this choice after receiving notification that your article has been
accepted for publication. The fee of $3,000 excludes taxes and other potential author fees such as color charges. In some cases, institutions
and funding bodies have entered into agreement with Elsevier to meet these fees on behalf of their authors. Details of these agreements
are available at
http://www.elsevier.com/fundingbodies. Authors of accepted articles, who wish to take advantage of this
option, should complete and submit the order form (available at
http://www.elsevier.com/locate/openaccessform.pdf). Whatever
access option you choose, you retain many rights as an author, including the right to post a revised personal version of your article
on your own website. More information can be found here:
http://www.elsevier.com/authorsrights.
Language and language services
Please write your text in good English (American or British usage is accepted,
but not a mixture of these). Authors who require information about language editing and copyediting services pre- and post-submission
please visit
http://webshop.elsevier.com/languageservices
or our customer support site at
http://support.elsevier.com
for more information.
Patient details
Unless you have written permission
from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and
in any supplementary materials (including all illustrations and videos) must be removed before submission. For further information see
http://www.elsevier.com/patientphotographs.
Submission
Submission
to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system
automatically converts source files to a single PDF file of the article, which is used in the peer-review process. Please note that even
though manuscript source files are converted to PDF files at submission for the review process, these source files are needed for further
processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place
by e-mail removing the need for a paper trail.
Submit your article
Please
submit your article via
http://ees.elsevier.com/jvac
Referees
Suggestions
for potential reviewers
Authors are invited to provide the names, and e-mail addresses of up to five potential reviewers. It
would not be appropriate to nominate individuals that have had any input into the manuscripts submitted or any recent collaboration with
the authors. The Editors may or may not take these suggestions into account during the reviewing process.
Review process
All
contributions are read by two or more referees to ensure both accuracy and relevance, and revisions to the script may thus be required.
On acceptance, contributions are subject to editorial amendment to suit house style. When a manuscript is returned for revision prior
to final acceptance, the revised version must be submitted as soon as possible after the author's receipt of the referee's reports. Revised
manuscripts returned after four months will be considered as new submissions subject to full re-review.
Use of wordprocessing software
It
is important that the file be saved in the native format of the wordprocessor used. The text should be in single-column format. Keep
the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular,
do not use the wordprocessor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts
etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If
no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional
manuscripts (see also the Guide to Publishing with Elsevier:
http://www.elsevier.com/guidepublication). Note that source
files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on
Electronic artwork.
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of
your wordprocessor.
Introduction
State the objectives of the work
and provide an adequate background, avoiding a detailed literature survey or a summary of the results.
Material and methods
Provide sufficient detail to allow the work to be reproduced, with details of supplier
and catalogue number when appropriate. Methods already published should be indicated by a reference: only relevant modifications should
be described.
Results
Results should be clear and concise.
Discussion
This should explore the significance of the results of the work, not repeat them. A combined
Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.
Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which
may stand alone or form a subsection of a Discussion or Results and Discussion section.
Essential title page information
•
Title.
Concise and informative. Titles are often used in information-retrieval
systems. Avoid abbreviations and formulae where possible.
•
Author names and affiliations.
Where the family name
may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work
was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in
front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available,
the e-mail address of each author.
•
Corresponding author.
Clearly indicate who will handle correspondence at
all stages of refereeing and publication, also post-publication.
Ensure that telephone and fax numbers (with country and area code)
are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding
author.
•
Present/permanent address.
If an author has moved since the work described in the article was done,
or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address
at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for
such footnotes.
Abstract
A concise and factual abstract is required. The
abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented
separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then
cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined
at their first mention in the abstract itself.
Graphical abstract
A Graphical
abstract is optional and should summarize the contents of the article in a concise, pictorial form designed to capture the attention
of a wide readership online. Authors must provide images that clearly represent the work described in the article. Graphical abstracts
should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 ×
1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution
of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. See
http://www.elsevier.com/graphicalabstracts for examples.
Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images also in accordance
with all technical requirements:
Illustration
Service.
Highlights
Highlights are mandatory for this journal.
They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate
file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters,
including spaces, per bullet point). See
http://www.elsevier.com/highlights for examples.
Stereochemistry abstract
For each important chiral compound you are requested to supply a stereochemistry
abstract detailing structure, name, formula and all available stereochemical information for eventual incorporation into a database.
An abstract for only one enantiomer per compound is required.
Keywords
Immediately
after the abstract, provide a maximum of 6 keywords, using British spelling and avoiding general and plural terms and multiple concepts
(avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible.
These keywords will be used for indexing purposes.
Abbreviations
Define
abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that
are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations
throughout the article.
Acknowledgements
Collate acknowledgements in a
separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote
to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing
assistance or proof reading the article, etc.).
Units
Follow internationally
accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent
in SI.
Database linking and Accession numbers
Elsevier aims at connecting
online articles with external databases which are useful in their respective research communities. If your article contains relevant
unique identifiers or accession numbers (bioinformatics) linking to information on entities (genes, proteins, diseases, etc.) or structures
deposited in public databases, then please indicate those entities according to the standard explained below.
Authors should explicitly
mention the
database abbreviation (as mentioned below) together with the actual database number, bearing in mind that an error
in a letter or number can result in a dead link in the online version of the article.
Please use the following format:
Database
ID: xxxx
Links can be provided in your online article to the following databases (examples of citations are given in parentheses):
•
GenBank: Genetic sequence database at the National Center for
Biotechnical Information (NCBI) (GenBank ID: BA123456)
•
PDB:
Worldwide Protein Data Bank (PDB ID: 1TUP)
•
CCDC: Cambridge Crystallographic
Data Centre (CCDC ID: AI631510)
•
TAIR: The Arabidopsis Information
Resource database (TAIR ID: AT1G01020)
•
NCT: ClinicalTrials.gov
(NCT ID: NCT00222573)
•
OMIM: Online Mendelian Inheritance
in Man (OMIM ID: 601240)
•
MINT: Molecular INTeractions
database (MINT ID: 6166710)
•
MI: EMBL-EBI OLS Molecular
Interaction Ontology (MI ID: 0218)
•
UniProt: Universal Protein Resource
Knowledgebase (UniProt ID: Q9H0H5)
Math formulae
Present simple formulae
in the line of normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y.
In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively
any equations that have to be displayed separately from the text (if referred to explicitly in the text).
Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article, using superscript
Arabic numbers. Many wordprocessors build footnotes into the text, and this feature may be used. Should this not be the case, indicate
the position of footnotes in the text and present the footnotes themselves separately at the end of the article. Do not include footnotes
in the Reference list.
Table footnotes
Indicate each footnote in a table with a superscript lowercase letter.
Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Save text in illustrations as 'graphics'
or enclose the font.
• Only use the following fonts in your illustrations: Arial, Courier, Times, Symbol.
• Number
the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
•
Provide captions to illustrations separately.
• Produce images near to the desired size of the printed version.
• Submit
each figure as a separate file.
A detailed guide on electronic artwork is available on our website:
http://www.elsevier.com/artworkinstructions
You are urged to visit this site; some excerpts from the detailed information are given here.
Formats
Regardless
of the application used, when your electronic artwork is finalised, please 'save as' or convert the images to one of the following formats
(note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
EPS: Vector drawings.
Embed the font or save the text as 'graphics'.
TIFF: Color or grayscale photographs (halftones): always use a minimum of 300 dpi.
TIFF: Bitmapped line drawings: use a minimum of 1000 dpi.
TIFF: Combinations bitmapped line/half-tone (color or grayscale): a
minimum of 500 dpi is required.
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel)
then please supply 'as is'.
Please do not:
• Supply files that are optimised for screen use (e.g., GIF, BMP, PICT,
WPG); the resolution is too low;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately
large for the content.
Color artwork
Please make sure that artwork
files are in an acceptable format (TIFF, EPS or MS Office files) and with the correct resolution. If, together with your accepted article,
you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color on the Web
(e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version.
For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.
Please indicate your preference for color: in print or on the Web only. For further information on the preparation of electronic artwork,
please see
http://www.elsevier.com/artworkinstructions.
Please note: Because of technical complications which can arise
by converting color figures to 'gray scale' (for the printed version should you not opt for color in print) please submit in addition
usable black and white versions of all the color illustrations.
Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a
brief title (
not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum
but explain all symbols and abbreviations used.
Tables
Number tables consecutively
in accordance with their appearance in the text. Place footnotes to tables below the table body and indicate them with superscript lowercase
letters. Avoid vertical rules. Be sparing in the use of tables and ensure that the data presented in tables do not duplicate results
described elsewhere in the article.
References
Citation in text
Please ensure that every reference cited in the text is also present in the reference
list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are
not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they
should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished
results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.
Web references
As a minimum, the full URL should be given and the date when the reference was last
accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given.
Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in
the reference list.
Reference style
Text: Indicate references
by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always
be given.
List: Number the references (numbers in square brackets) in the list in the order in which they appear in the
text.
Examples:
Reference to a journal publication:
[1] Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing
a scientific article. J Sci Commun 2010;163:51–9.
Reference to a book:
[2] Strunk Jr W, White EB. The elements of style.
4th ed. New York: Longman; 2000.
Reference to a chapter in an edited book:
[3] Mettam GR, Adams LB. How to prepare an electronic
version of your article. In: Jones BS, Smith RZ, editors. Introduction to the electronic age, New York: E-Publishing Inc; 2009, p. 281–304.
Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6 should be listed followed
by 'et al.' For further details you are referred to 'Uniform Requirements for Manuscripts submitted to Biomedical Journals' (J Am Med
Assoc 1997;277:927–34) (see also
http://www.nlm.nih.gov/bsd/uniform_requirements.html).
Journal abbreviations source
Journal names should be abbreviated according to
Index Medicus journal
abbreviations:
http://www.nlm.nih.gov/tsd/serials/lji.html;
List of title word abbreviations:
http://www.issn.org/2-22661-LTWA-online.php;
CAS (Chemical Abstracts Service):
http://www.cas.org/sent.html.
Supplementary
data
Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files
offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips
and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products,
including ScienceDirect:
http://www.sciencedirect.com. In order to ensure that your submitted material is directly usable,
please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with
the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction
pages at
http://www.elsevier.com/artworkinstructions.
Supplementary material
captions
Each supplementary material file should have a short caption which will be placed at the bottom of the article,
where it can assist the reader and also be used by search engines.
Google Maps and
KML files
KML (Keyhole Markup Language) files (optional): You can enrich your online articles by providing KML files which
will be visualized using Google maps. The KML files can be uploaded in our online submission system. KML is an XML schema for expressing
geographic annotation and visualization within Internet-based Earth browsers. Elsevier will generate Google Maps from the submitted KML
files and include these in the article when published online. Submitted KML files will also be available for downloading from your online
article on ScienceDirect. For more information see
http://www.elsevier.com/googlemaps.
Submission checklist
The following list will be useful during the final checking of an article prior to
sending it to the journal for review. Please consult this Guide for Authors for further details of any item.
Ensure that the following
items are present:
One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address
• Telephone and fax numbers
All necessary files have been uploaded, and contain:
•
Keywords
• All figure captions
• All tables (including title, description, footnotes)
Further considerations
•
Manuscript has been 'spell-checked' and 'grammar-checked'
• References are in the correct format for this journal
•
All references mentioned in the Reference list are cited in the text, and vice versa
• Permission has been obtained for use
of copyrighted material from other sources (including the Web)
• Color figures are clearly marked as being intended for color
reproduction on the Web (free of charge) and in print, or to be reproduced in color on the Web (free of charge) and in black-and-white
in print
• If only color on the Web is required, black-and-white versions of the figures are also supplied for printing purposes
For any further information please visit our customer support site at
http://support.elsevier.com.
Use of the Digital Object Identifier
The Digital Object Identifier (DOI) may be used to cite and link to
electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon
the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly
'Articles in press' because they have not yet received their full bibliographic information. The correct format for citing a DOI is shown
as follows (example taken from a document in the journal
Physics Letters B):
doi:10.1016/j.physletb.2010.09.059
When
you use the DOI to create URL hyperlinks to documents on the web, the DOIs are guaranteed never to change.
Proofs
One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do
not have an e-mail address then paper proofs will be sent by post) or, a link will be provided in the e-mail so that authors can download
the files themselves. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to download Adobe
Reader version 7 (or higher) available free from
http://get.adobe.com/reader. Instructions on how to annotate PDF files
will accompany the proofs (also given online). The exact system requirements are given at the Adobe site:
http://www.adobe.com/products/reader/tech-specs.html.
If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return
them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark
the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the
pages and e-mail, or by post. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text,
tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission
from the Editor. We will do everything possible to get your article published quickly and accurately – please let us have all your
corrections within 48 hours. It is important to ensure that all corrections are sent back to us in one communication: please check carefully
before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that
Elsevier may proceed with the publication of your article if no response is received.
Offprints
The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail. For an extra
charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. The PDF
file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining
the terms and conditions of use.
For inquiries relating
to the submission of articles (including electronic submission) please visit this journal's homepage. Contact details for questions arising
after acceptance of an article, especially those relating to proofs, will be provided by the publisher. You can track accepted articles
at
http://www.elsevier.com/trackarticle. You can also check our Author FAQs (
http://www.elsevier.com/authorFAQ)
and/or contact Customer Support via
http://support.elsevier.com.
